![Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres | Journal of Neurology, Neurosurgery & Psychiatry Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres | Journal of Neurology, Neurosurgery & Psychiatry](https://jnnp.bmj.com/content/jnnp/68/4/472/F4.large.jpg)
Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres | Journal of Neurology, Neurosurgery & Psychiatry
![Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres | Journal of Neurology, Neurosurgery & Psychiatry Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres | Journal of Neurology, Neurosurgery & Psychiatry](https://jnnp.bmj.com/content/jnnp/68/4/472/F3.large.jpg?width=800&height=600&carousel=1)
Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres | Journal of Neurology, Neurosurgery & Psychiatry
![Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies | Scientific Reports Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-018-36395-z/MediaObjects/41598_2018_36395_Fig3_HTML.png)
Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies | Scientific Reports
![Rituximab in the Treatment of Jo1 Antibody–associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response | The Journal of Rheumatology Rituximab in the Treatment of Jo1 Antibody–associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response | The Journal of Rheumatology](https://www.jrheum.org/content/jrheum/43/8/1566/F1.large.jpg)
Rituximab in the Treatment of Jo1 Antibody–associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response | The Journal of Rheumatology
![Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses | Cellular & Molecular Immunology Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses | Cellular & Molecular Immunology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41423-019-0331-0/MediaObjects/41423_2019_331_Fig1_HTML.png)
Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses | Cellular & Molecular Immunology
![PDF] Anti-Jo-1 antibodies in polymyositis or dermatomyositis: evaluation by ELISA using recombinant fusion protein Jo-1 as antigen. | Semantic Scholar PDF] Anti-Jo-1 antibodies in polymyositis or dermatomyositis: evaluation by ELISA using recombinant fusion protein Jo-1 as antigen. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/aa3d992fd6b0061526cf7d9c22279280c337724f/3-TableI-1.png)
PDF] Anti-Jo-1 antibodies in polymyositis or dermatomyositis: evaluation by ELISA using recombinant fusion protein Jo-1 as antigen. | Semantic Scholar
![Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres | Journal of Neurology, Neurosurgery & Psychiatry Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres | Journal of Neurology, Neurosurgery & Psychiatry](https://jnnp.bmj.com/content/jnnp/68/4/472/F1.large.jpg?width=800&height=600&carousel=1)